At present, there was one case report on pericardial effusion caused by alectinib (Ulhoi et al., 2021), but more case reports have shown that the symptoms of pericardial effusion can be effectively improved using ALK-TKIs (Gadgeel et al., 2014; Hao et al., 2015; Matsuo et al., 2016; Kasai et al., 2018). This evidence concerns the gene ALK and pericardial effusion.